FAP protein as specific marker for diagnosing central precocious puberty of obese girls and application of FAP protein

By detecting the expression level of FAP protein, providing kits for diagnosing central precocious puberty in obese girls and drug preparations that inhibit FAP protein expression, solving the problem of lack of reliable diagnostic markers in the prior art and realizing the centrality of obese girls Efficient diagnosis and treatment of sexual precocious puberty.

CN119001116APending Publication Date: 2024-11-22FUZHOU FIRST HOSPITAL (FUZHOU RED CROSS HOSPITAL FUZHOU INST OF CARDIOVASCULAR DISEASES)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411121441.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

There is a lack of reliable diagnostic markers for central precocious puberty in obese girls in the prior art, and there are few proteomic studies in existing studies, making it difficult to effectively diagnose the relationship between obesity and precocious puberty.

Method used

Using FAP protein as a specific marker, by detecting the expression level of FAP protein, a kit for diagnosing central precocious puberty in obese girls and a drug preparation that inhibits FAP protein expression is used to achieve diagnosis and treatment using serological detection technology.

Benefits of technology

Through the detection of FAP protein, an efficient diagnosis of central precocious puberty in obese girls was achieved. The ROC curve AUC was 0.94, which had good diagnostic value and provided a possible target for exploring the mechanism of affecting sexual development of obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119001116A_ABST
    Figure CN119001116A_ABST
Patent Text Reader

Abstract

The invention discloses an FAP protein as a specific marker for diagnosing central precocious puberty of obese girls and application of the FAP protein. A novel specific marker capable of being used for diagnosing central precocious puberty of obese girls is obtained through screening, and the specific marker is FAP protein. It is found through verification that the FAP protein is only highly expressed in obese girls with precocious puberty, and is lowly expressed in pure obese girls, pure precocious girls and normal girls. Based on the specific marker FAP protein, a serological detection technology is utilized to show that the ROC curve AUC of the specific marker for diagnosing central precocious puberty of obese girls is 0.94, and the specific marker FAP protein has good diagnostic value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to a FAP protein as a specific marker for diagnosing central precocious puberty in obese girls and an application thereof. Background Art

[0002] With the development of social economy, the incidence of precocious puberty is increasing and has become an increasingly serious public health problem. The incidence of precocious puberty in girls is significantly higher than that in boys. Precocious puberty can lead to the early appearance of secondary sexual characteristics, which may cause premature closure of the epiphysis and damage the height of the child throughout life, increase the risk of estrogen-related tumors in adulthood, and bring a series of psychosocial problems.

[0003] At present, some studies have analyzed the proteomics of girls with precocious puberty and found some differential proteins, suggesting that there are certain differences in protein levels between girls with precocious puberty and normal girls. In patients with central precocious puberty, the initiation of HPGA is usually considered to be the main diagnostic basis for central precocious puberty, so the evaluation of LH peak after GnRH stimulation is the gold standard for the diagnosis of central precocious puberty. The combination of basal hormone levels, pelvic ultrasound, bone age and pituitary MRI can improve the sensitivity and specificity of the diagnosis of central precocious puberty.

[0004] However, the LH peak of obese children is often lower than that of normal-weight children, which cannot reflect the sexual development status well. In existing literature reports, the patent document CN115804765A discloses the application of sodium propionate in obesity and precocious puberty and the treatment of obesity, which discloses drugs for treating obesity rather than diagnostic markers. Patent document CN114814236A discloses a specific biomarker containing glutamine, α-glucose, β-glucose, dihydroxyacetone, methionine, hypoxanthine, isobutyric acid, creatinine, valine, leucine and phenylalanine for diagnosing central precocious puberty in girls, but this specific biomarker is only for diagnosing central precocious puberty, not obesity with central precocious puberty. It can be seen that some problems still exist in the current research are: 1) There are few proteomic studies on the relationship between obesity and precocious puberty; 2) Reliable markers for central precocious puberty in obese girls have not yet been found.

[0005] Therefore, the development of rapid, sensitive and convenient diagnostic markers for central precocious puberty in obesity can not only help explore the pathogenesis of obesity-induced precocious puberty, but also has important significance for early disease diagnosis and prevention. Summary of the invention

[0006] In view of the deficiencies of the prior art, the object of the present invention is to provide a FAP protein as a specific marker for diagnosing central precocious puberty in obese girls and its application.

[0007] The objective of the present invention is achieved through the following technical solutions:

[0008] In a first aspect, the present invention provides a use of a FAP protein as a specific marker in the preparation of a diagnostic product for central precocious puberty in obese girls.

[0009] As a preferred embodiment, the FAP protein is highly expressed in obese girls with central precocious puberty.

[0010] As a preferred embodiment, the diagnostic product is a kit.

[0011] As a preferred embodiment, the kit includes a reagent for detecting the expression level of FAP protein in the sample to be tested.

[0012] As a preferred embodiment, when the expression level of the FAP protein is greater than 10.00 ng / mL, it can be preliminarily diagnosed as central precocious puberty.

[0013] As a preferred embodiment, the sample to be tested is any one of whole blood, plasma and serum.

[0014] As a preferred embodiment, the reagents include washing buffer, standard substance, biotin-labeled antibody, sample diluent, antibody dilution buffer, stop solution, and color development reagent.

[0015] As a preferred embodiment, the obese girls include girls aged 6 years old with BMI>18.4, girls aged 7 years old with BMI>18.8, girls aged 8 years old with BMI>19.5, girls aged 9 years old with BMI>20.4, and girls aged 10 years old with BMI>21.5.

[0016] In a second aspect, the present invention provides a method for preparing a diagnostic product for central precocious puberty in obese girls using a reagent for detecting the expression level of FAP protein.

[0017] As a preferred embodiment, the diagnostic product is a kit.

[0018] As a preferred embodiment, the reagents include washing buffer, standard substance, biotin-labeled antibody, sample diluent, antibody dilution buffer, stop solution, and color development reagent.

[0019] In a third aspect, the present invention provides the use of a product for inhibiting the expression of FAP protein in the preparation of a pharmaceutical preparation for treating and / or preventing central precocious puberty in obese girls.

[0020] As a preferred embodiment, the product for inhibiting the expression of FAP protein includes a FAP inhibitor.

[0021] As a preferred embodiment, the FAP inhibitor is selected from SP-13786.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] 1. The present invention obtains a new specific marker for diagnosing central precocious puberty in obese girls through screening, and the specific marker is FAP protein. It has been verified that the FAP protein is only highly expressed in obese girls with precocious puberty, and is lowly expressed in simple obese girls, simple precocious girls and normal girls.

[0024] 2. Based on the specific marker FAP protein, using serological detection technology, it was shown that the ROC curve AUC for diagnosing central precocious puberty in obese girls was 0.94, which has good diagnostic value.

[0025] 3. The present invention provides a possible target for further exploring the mechanism by which obesity affects sexual development. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:

[0027] Figure 1 Technical flow chart for identifying serum samples associated with precocious puberty in obese girls using protein profiling technology;

[0028] Figure 2 The results of serum protein group difference analysis between the two groups of patients with precocious puberty;

[0029] Figure 3 is the ROC curve of biomarkers FAP, ALP, and IGF-1; Figure 3 A is the AUC result of each biomarker in the precocious puberty group and the non-precocious puberty group; Figure 3 B is the AUC results of each biomarker in the obese precocious puberty group and the simple precocious puberty group;

[0030] Figure 4 The results are for the expression levels of the fap gene in the whole zebrafish of each group;

[0031] Figure 5 The results of immunofluorescence detection of gonadal VASA antibody in each group of zebrafish (three samples). DETAILED DESCRIPTION

[0032] The present invention is described in detail below in conjunction with specific embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. It should be noted that, for those of ordinary skill in the art, several variations and improvements may be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.

[0033] FAP is a serine hydrolase, whose subunit composition includes a β-helical domain and an α / β-hydrolysis catalytic domain. It is a member of the type II serine protease family. It can act as both a dipeptidyl peptidase and a collagenase in vitro. It was identified as an antigen in fibroblasts cultured with the monoclonal antibody F19 in 1986. FAP has a rare catalytic activity, hydrolyzing two or more residues after the proline bond from the N-terminus of the target substrate. In most tissues of adults, FAP is weakly expressed or not expressed at all. However, it can be detected in mesenchymal tissues during embryonic development and in pathological conditions in adults, including fibrosis, arthritis, cardiovascular disease, and tumors. Current studies have shown that FAP is associated with fibrosis, cell migration, and apoptosis, and may be involved in multiple processes such as chronic inflammation and malignant tumor growth, making this protease a potential therapeutic target. For example, FAP regulates the repair of myocardial infarction damage, and inhibition of FAP can promote angiogenesis and cardiac repair by stabilizing the level of brain natriuretic peptide protein. In existing reports, there has been no report on the correlation between FAP and central precocious puberty in obese girls. The amino acid sequence of FAP (SEQ ID NO.1) is as follows:

[0034] MKTWVKIVFGVATSAVLALLVMCIVLRPSRVHNSEENTMRALTLKDILNGTFSYKTFFPNWISGQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNASNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLSNGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYLKQRPGDPPFQITFNGREN KIFNGIPDWVYEEEMLATKYALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYPRTINIPYPKAGAKNPVVRIFIIDTTYPAYVGPQEVPVPAMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVLSICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVSTPVFSYDAISYYKIFSDKDGYKHIHYI KDTVENAIQITSGKWEAINIFRVTQDSLFYSSNEFEEYPGRRNIYRISIGSYPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVCYGPGIPISTLHDGRTDQEIKILEENKELENALKNIQLPKEEIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVYGGPCSQSVRSVFAVNWISYLASKEGMVIA LVDGRGGTAFQGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFIDEKRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVSSWEYYASVYTERFMGLPTKDDNLEHYKNSTVMARAEYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQVDFQAMWYSDQNHGLSGSTNHLYTHMTHFLKQCFSLSD

[0035] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.

[0036] Example 1 Marker Screening

[0037] In this example, protein spectrum technology is used to identify serum samples related to precocious puberty. The technical process is as follows: Figure 1 As shown, the specific steps are as follows:

[0038] 1. Sample Grouping

[0039] Four types of serum samples, 10 cases each, were selected. Their age, height, weight, BMI and other information are shown in Table 1. The results showed that there was no significant difference in age among the four groups of patients.

[0040] Table 1 General information of the subjects

[0041] Grouping Age (years) Height (cm) Weight(kg) <![CDATA[BMI(kg / m 2 )]]> Obese precocious puberty group 8.27±0.45 138.57±6.99 42.66±5.54 22.16±1.95 Simple obesity group 8.02±0.65 133.50±5.80 40.72±6.30 22.80±2.57 Simple precocious puberty group 8.01±0.37 133.54±4.43 27.61±3.46 15.45±1.30 Control group 8.13±0.67 122.71±5.33 22.23±4.17 14.64±1.51

[0042] 2. Proteomics screening of differentially expressed proteins in each group

[0043] 1. Protein extraction:

[0044] Serum samples were taken out from -80℃ and analyzed by Pierce TM The Albumin Serum Depletion Kit removes IgG and albumin. This kit uses a classic mixture of Cibacron blue dye and protein A resin to remove albumin and IgG. The dye binds to albumin with good specificity, while protein A binds to IgG. The specific method is as follows: dilute the serum sample to 75μL with PBS buffer, add the diluted serum sample to the pretreated separation column, remove the bottom plug from the column and loosen the cap, return the column to the microcentrifuge tube, and centrifuge at 10000g for 1min. The filtered sample is the serum protein with IgG and albumin removed. Protein concentration is determined using BSA.

[0045] 2. Enzymatic hydrolysis with pancreatic enzymes:

[0046] Take an equal amount of each sample protein for enzymatic hydrolysis, add an appropriate amount of standard protein, and adjust the volume to the same with lysis buffer. Slowly add TCA at a final concentration of 20%, vortex to mix, and precipitate at 4°C for 2h. Centrifuge at 4500g for 5min, discard the supernatant, and wash the precipitate with pre-cooled acetone 2-3 times. After drying the precipitate, add TEAB at a final concentration of 200mM, ultrasonically break up the precipitate, add trypsin at a ratio of 1:50 (protease: protein, m / m), and enzymatic hydrolysis overnight. Add dithiothreitol (DTT) to a final concentration of 5mM, and reduce at 56°C for 30min.

[0047] Then, iodoacetamide (IAA) was added to make the final concentration 11 mM, and the mixture was incubated at room temperature in the dark for 15 min.

[0048] 3.TMT Mark:

[0049] The peptides obtained by trypsin digestion in step 2 were desalted with Strata X C18 (Phenomenex) and then freeze-dried in vacuum. The peptides were dissolved in 0.5M TEAB and labeled according to the TMT kit instructions. The simple operation is as follows: the labeling reagent is thawed and dissolved in acetonitrile, mixed with the peptides and incubated at room temperature for 2 hours, the labeled peptides are mixed and desalted, and then freeze-dried in vacuum.

[0050] 4.HPLC classification:

[0051] The TMT-labeled peptides were fractionated by high pH reverse phase HPLC, using an Agilent 300Extend C18 column (5 μm particle size, 4.6 mm inner diameter, 250 mm length). The operation was as follows: the peptide fractionation gradient was 8%-32% acetonitrile, pH 9, and 60 fractions were separated in 60 min. The peptides were then combined into 9 fractions, and the combined fractions were freeze-dried in vacuum for subsequent operations.

[0052] 5. Liquid chromatography-mass spectrometry analysis:

[0053] The combined peptides were dissolved in liquid chromatography mobile phase A and separated using the EASY-nLC 1200 ultra-high performance liquid phase system. Mobile phase A was an aqueous solution containing 0.1% formic acid and 2% acetonitrile; mobile phase B was an aqueous solution containing 0.1% formic acid and 90% acetonitrile. The liquid phase gradient was set as follows: 0-36min, 6% to 22% B; 36-52min, 22% to 32% B; 52-56min, 32% to 80% B; 56-60min, 80% B, and the flow rate was maintained at 500nL / min. After the peptides were separated by the ultra-high performance liquid phase system, they were injected into the NSI ion source for ionization and then into the Q Exactive TM HF-X mass spectrometry was used for analysis. The ion source voltage was set to 2.1 kV, and the peptide parent ions and their secondary fragments were detected and analyzed using a high-resolution Orbitrap. The primary mass spectrometry scan range was set to 350-1600 m / z, and the scan resolution was set to 120,000; the secondary mass spectrometry scan range was fixed at 100 m / z, and the secondary scan resolution was set to 45,000. The data acquisition mode used a data-dependent scan (DDA) program, that is, after the primary scan, the top 20 peptide parent ions with the highest signal intensity were selected to enter the HCD collision cell in turn and use 28% fragmentation energy for fragmentation, and the secondary mass spectrometry analysis was also performed in turn. In order to improve the effective utilization of the mass spectrometry, the automatic gain control (AGC) was set to 1E5, the signal threshold was set to 8.3E4ions / s, the maximum injection time was set to 60ms, and the dynamic exclusion time of the tandem mass spectrometry scan was set to 30s to avoid repeated scanning of the parent ion.

[0054] 6. Perform database search after the mass spectrometer is off the machine:

[0055] Database retrieval is a complex calculation process, which requires the use of professional mass spectrometry data analysis software for data analysis. The raw data from the mass spectrometer is imported into the search software, and the corresponding analysis parameters are set according to the experimental plan. The secondary mass spectrometry data of this experiment was retrieved using Proteome Discoverer (v2.4.1.15). Retrieval parameter settings: The database is Homo_sapiens_9606_SP_20210721.fasta (20387 sequences), and the reverse library is added to calculate the false positive rate (FDR) caused by random matching, and a common contamination library is added to the database to eliminate the influence of contaminating proteins in the identification results; the enzyme cutting mode is set to Trypsin (Full); the number of missed cutting sites is set to 2; the minimum length of the peptide is set to 6 amino acid residues; the maximum number of peptide modifications is set to 3; the primary parent ion mass error tolerance is set to 10ppm, and the secondary fragment ion mass error tolerance is 0.02Da. Carbamidomethyl (C), TMT16plex (peptide N-Terminus), TMT16plex (K) were set as fixed modifications, and Acetyl (protein N-Terminus), Oxidation (M) were set as variable modifications. The quantitative method was set to TMT-16plex, and the FDR for protein, peptide, and PSM identification was set to 1%. In order to obtain high-quality analysis results, the search results required further data filtering. The accuracy FDR of identification at the three levels of spectrum, peptide, and protein was set to 1%; the identified protein must contain at least one unique peptide.

[0056] 7. Data quality control:

[0057] After the database search is completed, the data from the mass spectrometer needs to undergo a series of quality control evaluations to ensure that the quality of the results meets the standards: including peptide length distribution, peptide number distribution, protein coverage distribution, and protein molecular weight distribution. In the mass spectrometry analysis method based on the shotgun (also called bottom-up) strategy, the mass spectrometer preferentially scans peptides with higher abundance.

[0058] 8. Quantitative analysis of protein:

[0059] The search results give the signal intensity value (Reporter Intensity) of each peptide in different samples. Based on this information, the relative quantitative value of the protein is calculated through the following steps:

[0060] First, the signal intensity values ​​(I) of peptides in different samples are transformed by centering to obtain the relative quantitative values ​​(U) of peptides in different samples. The calculation formula is as follows: where i represents the sample and j represents the peptide.

[0061] Uij=Iij / Mean(Ij)Uij=Iij / Mean(Ij)

[0062] In order to eliminate the systematic error of the loading amount of different samples in mass spectrometry detection, the relative quantitative value of peptides needs to be corrected using the median normalization method (NR). The calculation formula is as follows:

[0063] NRij=Uij / Median(Ui)NRij=Uij / Median(Ui)

[0064] The relative quantitative value (R) of a protein is expressed as the median of the relative quantitative values ​​of the specific peptides corresponding to the protein. The calculation formula is as follows: where k represents the protein and j represents the specific peptide to which the protein belongs.

[0065] Rik=Median(NRij,j∈k)

[0066] 9. Sample repeatability test:

[0067] For biological replicates or technical replicates, it is necessary to check whether the quantitative results of biological replicates or technical replicates meet the statistical consistency. Here, three statistical analysis methods, Pearson's Correlation Coefficient (PCC), principal component analysis (PCA) and relative standard deviation (RSD), are used to evaluate repeatability. Heat map drawn by the Pearson correlation coefficient between all samples. This coefficient is used to measure the degree of linear correlation between two sets of data: the Pearson correlation coefficient is close to -1 for negative correlation, close to 1 for positive correlation, and close to 0 for no correlation. The results of the principal component analysis of protein quantification of all samples are displayed in the figure. The degree of aggregation between samples in the figure represents the difference between samples. The box plot of the relative standard deviation (RSD) of the protein quantitative values ​​between each group of repeated samples. The smaller the overall RSD value, the better the quantitative repeatability.

[0068] 10. Screening of differentially expressed proteins in four groups:

[0069] Three or more replicates: First, select the samples to be compared, and take the ratio of the mean relative quantitative values ​​of each protein in multiple replicate samples as the fold change (FC). For example, calculate the fold change of protein between sample A and sample B. The calculation formula is as follows:

[0070] Where R represents the relative quantitative value of protein, i represents sample, and k represents protein.

[0071] FCA / B,k=Mean(Rik,i∈A) / Mean(Rik,i∈B)

[0072] In order to determine the significance of the difference, the relative quantitative value of each protein in the comparison group samples was subjected to a T test, and the corresponding P value was calculated as a significance indicator, with the default P value < 0.05. In order to make the test data conform to the normal distribution required by the T test. Before the test, the relative quantitative value of the protein needs to be transformed by Log2. The calculation formula is as follows:

[0073] Pik=T.test(Log2(Rik,i∈A),Log2(Rik,i∈B))

[0074] Repeat twice: First, select the samples to be compared, and take the mean of the relative quantitative values ​​of each protein in the two repeated comparison groups as the fold change (FC). For example, calculate the fold change of protein between sample group A and sample group B. The calculation formula is as follows: where R represents the relative quantitative value of protein, i represents the sample, and k represents the protein.

[0075] FCA / B,k=Mean((Rik,i∈A) / (Rik,i∈B))

[0076] In order to judge the significance of the difference, the standard coefficient of variation (CV) of each protein in the comparison group was used as a significance indicator, and the default CV<0.1. The calculation formula is as follows:

[0077] CV=SD(A1k / B1k,A2k / B2k) / Mean(A1k / B1k,A2k / B2k)

[0078] No duplication: First, select the samples to be compared, and take the ratio of the relative quantitative value of each protein in the sample as the fold change (FC). For example, calculate the fold change of the protein between sample A and sample B. The calculation formula is as follows: Where R represents the relative quantitative value of the protein, and k represents the protein.

[0079] FCA / B,k=RAk / RBk

[0080] In order to determine the significance of the difference, the relative quantitative value of the peptide segment of each protein was subjected to a T test in the comparison group, and the corresponding P value was calculated as a significance indicator, with a default P value of <0.05. In order to make the test data conform to the normal distribution required by the T test. Before the test, the relative quantitative value of the peptide segment needs to be transformed by Log2. The calculation formula is as follows: Where U represents the relative quantitative value of the peptide segment, and j represents the peptide segment.

[0081] Pk=T.test(Log2(UAj),Log2(UBj),j∈k)

[0082] Through the above difference analysis, when P value <0.05, the difference expression change exceeding 1.3 was regarded as the threshold of significant upregulation, and less than 1 / 1.3 was regarded as the threshold of significant downregulation.

[0083] In order to study the serum proteome characteristics of two different types of precocious puberty, the above mass spectrometry data were divided into two categories for analysis, namely, obese precocious puberty vs simple obesity, representing differential proteins in obesity-related precocious puberty; simple precocious puberty vs normal control, representing differential proteins in simple precocious puberty. The results showed that 83 differential proteins were identified in obesity-related precocious puberty, while 53 differential proteins were identified in simple precocious puberty, of which 12 proteins appeared in both groups ( Figure 2 ), the 12 proteins are: FAP, COL5A2, CHAD, MEPE, PRG2, GGH, CKM, GALNT5, AGRN, PF4V1, LIMS1, and FTL.

[0084] 3. Bioinformatics analysis of differentially expressed proteins and protein interaction network analysis

[0085] In order to further study the differential characteristics of serum proteomes in the two groups of patients with precocious puberty, the 12 differential proteins were subjected to functional enrichment and annotation analysis. The results of enrichment analysis and functional annotation of differential proteins showed that the functions of serum differential proteins in the two groups of patients with precocious puberty were highly similar, and concentrated in pathways such as insulin receptor, amino acid biosynthesis, and inflammatory response.

[0086] On the basis of the above differential protein analysis, the proteins with high expression in the serum of patients with obese precocious puberty and no significant difference in simple obesity were selected for the next step of analysis. The down-regulated proteins and the differential proteins of simple precocious puberty were eliminated. The results showed that among the up-regulated proteins, FAP had the most significant difference in the obese precocious puberty group. Further, the random forest algorithm in machine learning was used to calculate the weights of each protein in obese precocious puberty patients. The results showed that the results tended to be stable after 104 iterations of training, among which type V collagen alpha 2 (collagentype Valpha 2, COL5A2) and FAP scored the highest in the model.

[0087] The specific method of the above analysis is:

[0088] 1. Based on the KEGG pathway database, the protein pathways were annotated, and the identified proteins were BLAST-matched (blastp, evalue ≤ 1e-4). For each BLAST-matched result of a sequence, the one with the highest score was selected for annotation. We compared the database and performed COG / KOG functional classification statistics on the differentially expressed proteins. The pathways obtained by analysis were visualized and plotted using the stringr, plyr, and Hmisc packages of the R language. The execution code is as follows:

[0089] rm(list=ls()); options(stringsAsFactors=F)

[0090]

[0091] 2. After the differential proteins were compared with the STRING (v.11.5) protein interaction network database, the differential protein interaction relationships were extracted according to the confidence score 0.7 (high confidence). Finally, the differential proteins were compared with the STRING (v.11.5) protein interaction network database, and the differential protein interaction relationships were extracted according to the confidence score 0.7 (high confidence). The interaction results were imported into the Cytoscape software.

[0092] 3. Upload the differentially expressed proteins identified by mass spectrometry to the PANTHER database (http: / / www.pantherdb.org / ), select human as the species, select Functional classification viewed in graphic charts as the analysis type, and perform analysis in the Biological process and Pathway modules respectively. Finally, export the classification pie chart and annotation information.

[0093] 4. Use the randomForest package of R language to perform random forest training. The specific method and code are as follows:

[0094]

[0095] 4. Enzyme linked immunosorbent assay (ELISA) to verify differentially expressed proteins

[0096] In order to verify the potential of FAP protein as a biomarker of central precocious puberty in obese girls, based on the existing serum samples, 10 serum samples were collected from obese precocious puberty, simple obesity, simple precocious puberty and normal control groups, and there was no significant difference in age. The FAP protein in each serum sample was detected by ELISA technology, and the IGF-1 (insulin-like growth factor-1, which has been clinically confirmed to be increased in children with precocious puberty) in each serum sample was detected by chemiluminescence method, and the ALP (serum alkaline phosphatase, which has been clinically confirmed to be increased in children with precocious puberty) in each serum sample was detected by automatic biochemical detector.

[0097] ELISA technology was used to detect FAP protein using the FAP ELISA kit (Fine Test). The specific steps are as follows:

[0098] 1. Washing buffer: If crystals have formed in the concentrated washing buffer, heat it in a 40°C water bath (the heating temperature should not exceed 50°C) and mix gently until the crystals are completely dissolved. The concentrated washing buffer should be cooled to room temperature before use. Dilute 30ml (15ml for 48T) of concentrated washing buffer to 750ml (375ml for 48T) of washing buffer with deionized or distilled water (the recommended resistivity of deionized or distilled water is 18MΩ). Return the unused concentrated washing buffer to 2-8°C.

[0099] 2. Standard: Add 1 mL of standard (FAP protein concentration is 0.1 μg / mL) to a standard tube (labeled as zero tube) and incubate at room temperature for 10 minutes to obtain a standard solution.

[0100] 3. Label 7 EP tubes with 1 / 2, 1 / 4, 1 / 8, 1 / 16, 1 / 32, 1 / 64 and blank labels respectively. Add 0.3 ml of standard solution from the zero tube to the first tube (1 / 2 tube), add sample dilution buffer to make up to 0.6 ml, and mix thoroughly to obtain standard solution 1. Transfer 0.3 ml of standard solution 1 from the first tube to the second tube (1 / 4 tube), add sample dilution buffer to make up to 0.6 ml, and mix thoroughly to obtain standard solution 2. Transfer 0.3 ml of standard solution 2 from the second tube to the third tube (1 / 8 tube), add sample dilution buffer to make up to 0.6 ml, and mix thoroughly to obtain standard solution 3, and so on to the sixth tube (1 / 64 tube). Use sample dilution buffer for the blank tube. Note: It is best to use the standard solution within 2 hours.

[0101] 4. Preparation of biotinylated antibody working solution: Prepare within 1 hour before the experiment. ① Calculate the total volume of the working solution required: 0.1 ml / well. ② Dilute the biotinylated antibody (provided by the kit) at 1:100 with antibody dilution buffer and mix thoroughly (i.e. add 1 ul of biotinylated antibody to 99 ul of antibody dilution buffer).

[0102] 5. Preparation of HRP-streptavidin conjugate (SABC) working solution: Prepare within 30 minutes before the experiment. ① Calculate the total amount of working solution required: 0.1 ml / well. ② Dilute SABC with SABC dilution buffer at 1:100 and mix thoroughly (i.e. add 1 ul SABC to 99 ul SABC dilution buffer).

[0103] 6. TMB substrate was equilibrated at 37°C for 30 minutes before adding TMB developer (Sigma) to the wells.

[0104] 7. Set up standard wells, sample wells, and control (blank) wells on the plate and record their positions. It is recommended to measure each standard and sample in duplicate.

[0105] 8. Prepare standard products: dispense 100ul of each standard solution in tube zero, tube 1, tube 2, tube 3, tube 4, tube 5, and tube 6 into the standard wells, and dispense the sample dilution buffer in the blank tube into the control wells.

[0106] 9. Sample addition: Add 100ul of appropriately diluted serum samples (diluted at least 1 / 2 with sample dilution buffer) to the sample wells.

[0107] 10. Incubation: Seal the plate with a lid and incubate at 37°C for 90 minutes.

[0108] 11. Washing: Remove the cover plate, discard the liquid (pat manually with moderate force), and wash twice with washing buffer. Do not let the plate dry completely at any time.

[0109] 12. Biotin-labeled antibody: Add 100ul of biotin-labeled antibody working solution to the above wells (standard wells, sample wells, and blank wells). Add the solution to the bottom of each well without touching the side walls, cover the plate, and incubate at 37°C for 60 minutes.

[0110] 13. Washing: Remove the cover and wash three times with washing buffer, allowing the washing buffer to stay in the well for 1-2 minutes each time and discarding the liquid (pat manually with medium force).

[0111] 14. HRP-streptavidin conjugate (SABC): Add 100ul SABC working solution to each well, cover the plate, and incubate at 37°C for 30 minutes.

[0112] 15. Washing: Remove the cover plate and wash 5 times with washing buffer, leaving the washing buffer in the well for 1-2 minutes each time. Discard the solution (pat manually with medium force).

[0113] 16. TMB color development: Add 90ul TMB color developer to each well and incubate at 37℃ in the dark for 10-20 minutes (Note: the reaction time can be shortened or extended according to the actual color change, but cannot exceed 30 minutes). When a clear gradient appears in the standard well, the reaction can be terminated. Stop: Add 50ul ELISA stop solution (Shanghai Biotech) to each well. The color turns yellow. The order of adding the stop solution should be the same as that of TMB. OD value measurement: After adding the stop solution, immediately read the OD value at 450nm on the microplate reader.

[0114] The detection steps of IGF-1 in each serum sample are as follows: IGF-1 chemiluminescence assay kit (Siemens) is used for detection, and the double antibody sandwich method is used to coat the ELISA plate with anti-human IGF-1 antibody. During the experiment, IGF-1 in the specimen or standard will bind to the coated antibody, and the free components will be washed away. Biotinylated anti-human IGF-1 antibody and horseradish peroxidase-labeled avidin are added in sequence, the anti-human IGF-1 antibody binds to the human IGF-1 bound to the coated antibody, and biotin specifically binds to avidin to form a complex, and the free components are washed away, and a luminescent substrate mixture is added. The luminescent substrate emits fluorescence under the catalysis of horseradish peroxidase, and the chemiluminescence value RLU is measured using the fully automatic chemiluminescence immunoassay instrument IMMULITE 2000. There is a positive correlation between the IGF-1 concentration and the chemiluminescence value, and the concentration of IGF-1 in the specimen is obtained by drawing the standard center line.

[0115] The detection steps of ALP of each serum sample are as follows: using Olympus fully automatic biochemical analyzer for continuous monitoring, continuously measuring the change of product amount over time at regular intervals (2-60s), calculating the initial velocity of enzyme reaction, and indirectly obtaining the enzyme activity value.

[0116] The test results are shown in Table 2.

[0117] Table 2

[0118]

[0119]

[0120] The patients were divided into precocious puberty group and non-precocious puberty group to compare the test results ( Figure 3 ),like Figure 3As shown in Figure A, the results show that FAP and the two indicators ALP and IGF-1 used in clinical practice have good diagnostic value (AUC>0.8), and the ROC curve AUCs are FAP (0.95), ALP (0.83) and IGF-1 (0.96), respectively. Further, the patients with precocious puberty were divided into the obese precocious puberty group and the simple precocious puberty group to compare the test results, as shown in Figure 1. Figure 3 As shown in Figure B, the results showed that FAP still had good diagnostic value (AUC>0.9), and its ROC curve AUC was 0.94; but the AUCs of ALP and IGF-1 dropped to 0.56 and 0.78, indicating that ALP and IGF-1 did not have good diagnostic value.

[0121] Example 2

[0122] To further verify the role of FAP in obesity-related development, this example uses zebrafish as the research subject, applies high-fat diet and overfeeding methods to establish an obese female zebrafish model, constructs a zebrafish control group, an obese group (undeveloped) and an obese development group, and uses qRT-PCR and in situ hybridization to detect the expression of the fap gene; at the same time, the obese zebrafish are intervened with FAP inhibitors, and the gonads are isolated for immunofluorescence to observe the development of germ cells. The specific experimental steps are as follows:

[0123] Healthy zebrafish (wild-type AB strain zebrafish, from Fujian Institute of Medical Sciences) eggs were incubated at a constant temperature. Healthy female zebrafish larvae were selected 5 days after fertilization and opened with paramecium. On the 15th day, brine shrimp was appropriately fed. The control group was fed normally, and the obese (undeveloped) zebrafish model group and the obese (developed) zebrafish model group were fed with egg yolk powder twice a day. The breeding water was changed once a day. On the 31st day, the obese (undeveloped) zebrafish model group weighed (68±21) mg, and the control group weighed (32±11) mg. At this time, the total RNA of the obese (undeveloped) zebrafish model group and the control group was extracted; while the obese (developed) zebrafish model group continued to be fed until the 45th day (according to the literature, normal female zebrafish enter puberty when the body weight reaches 100 mg on the 45th day), and the body weight reached (145±36) mg. At this time, the total RNA of the obese (developed) zebrafish model group was extracted. The expression levels of the fap gene in the three groups of zebrafish were detected using conventional methods. Figure 4 As shown, there was no difference in the expression level of the fap gene between the control group and the obese (undeveloped) zebrafish model group, while the expression level in the obese (developed) zebrafish model group was significantly increased.

[0124] The gonads and brain of the obese (developmental) zebrafish model group were further separated, and the results of in situ hybridization showed that the fap gene was lowly expressed or even not expressed in the brain, but highly expressed in the gonads. In order to further explore the correlation between FAP and zebrafish puberty (gonadal) development, FAP inhibitor (SP-13786, 1uM / mL) was used for intervention. The obese (developmental) zebrafish model was constructed using the same method as mentioned above. At 27 days, the zebrafish in the obese (developmental) intervention group began to add FAP inhibitors, while the zebrafish in the obese (developmental) group were given 1% DMSO as a control, and the intervention time was 18d. In addition, the control group was fed normally. At 45 days, the weight of the control group was (102±29) mg, the weight of the obese (developmental) group was (145±36) mg, and the weight of the obese (developmental) intervention group was (138±40) mg. The vasa gene is a germ cell marker gene and is only expressed in germ cells. We used VASA antibodies to mark germ cells, and immunofluorescence results showed that ( Figure 3 .4), the number of germ cells in the obesity (development) group was significantly more than that in the control group; the VASA expression level in the obesity (development) intervention group with FAP intervention decreased, indicating a decrease in germ cells and blocked gonadal development.

[0125] Application Examples

[0126] Based on the results of the above examples, FAP protein was used as a diagnostic marker for the detection of central precocious puberty in obese girls. The same FAP ELISA diagnostic kit as in Example 1 was used for detection. The judgment criteria for the test results were as follows:

[0127] FAP protein expression > 10.00 ng / mL: This obese girl can be preliminarily diagnosed as a patient with central precocious puberty

[0128] FAP protein expression <= 10.00 ng / mL: This obese girl cannot be diagnosed as a patient with central precocious puberty

[0129] This proves the feasibility of the method of the present invention.

[0130] The present invention has many specific application paths, and the above is only a preferred embodiment of the present invention. It should be pointed out that the above embodiments are only used to illustrate the present invention, and are not used to limit the protection scope of the present invention. For those of ordinary skill in the art, several improvements can be made without departing from the principle of the present invention, and these improvements should also be regarded as the protection scope of the present invention.

Claims

1. Application of FAP protein as a specific marker in the preparation of a diagnostic product for central precocious puberty in obese girls.

2. The use according to claim 2, characterized in that: The FAP protein is highly expressed in obese girls with central precocious puberty.

3. The use according to claim 1, characterized in that: The diagnostic product is a kit.

4. The use according to claim 3, characterized in that: The kit comprises a reagent for detecting the expression level of FAP protein in a sample to be tested.

5. The use according to claim 4, characterized in that: When the expression level of the FAP protein is greater than 10.00 ng / mL, it can be preliminarily diagnosed as central precocious puberty.

6. The use according to claim 4, characterized in that: The sample to be tested is any one of whole blood, plasma and serum.

7. The use according to claim 4, characterized in that: The reagents include washing buffer, standard substance, biotin labeled antibody, sample diluent, antibody dilution buffer, stop solution and color developing reagent.

8. The use according to claim 1, characterized in that: The obese girls include girls aged 6 years with BMI>18.4, girls aged 7 years with BMI>18.8, girls aged 8 years with BMI>19.5, girls aged 9 years with BMI>20.4, and girls aged 10 years with BMI>21.

5.

9. Use of a reagent for detecting the expression level of FAP protein in the preparation of a diagnostic product for central precocious puberty in obese girls.

10. Use of a product for inhibiting the expression of FAP protein in the preparation of a pharmaceutical preparation for treating and / or preventing central precocious puberty in obese girls.